These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Recurrence of migraine with aura due to tacrolimus therapy in a liver transplant recipient successfully treated with sirolimus substitution. Toth CC; Burak K; Becker W Headache; 2005 Mar; 45(3):245-6. PubMed ID: 15836601 [TBL] [Abstract][Full Text] [Related]
47. Sirolimus: more cause for alarm? Agarwal PD; Lucey MR Liver Transpl; 2012 Sep; 18(9):1003-4. PubMed ID: 22639401 [No Abstract] [Full Text] [Related]
48. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection. Cowan PA; Heizer KE Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344 [TBL] [Abstract][Full Text] [Related]
49. Inferior results with basis immunosuppression with sirolimus in kidney transplantation. van den Akker JM; Hené RJ; Hoitsma AJ Neth J Med; 2007 Jan; 65(1):23-8. PubMed ID: 17293636 [TBL] [Abstract][Full Text] [Related]
50. De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Crew RJ; Radhakrishnan J; Cohen DJ; Stern L; Goldstein M; Hardy M; D'Agati VD; Markowitz GS Nephrol Dial Transplant; 2005 Jan; 20(1):203-9. PubMed ID: 15632351 [No Abstract] [Full Text] [Related]
51. Simultaneous PRES and TMA secondary to tacrolimus after allogeneic bone marrow transplant. Aruch DB; Renteria A Blood; 2015 Jun; 125(25):3963. PubMed ID: 26287041 [No Abstract] [Full Text] [Related]
52. Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome. Catalano G; De Simone P; Mazzoni A; Ghinolfi D; Coletti L; Filipponi F Transpl Int; 2014 Sep; 27(9):e84-6. PubMed ID: 24606320 [No Abstract] [Full Text] [Related]
53. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF; Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398 [TBL] [Abstract][Full Text] [Related]
54. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? Hanto DW; Chudzinski R Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968 [No Abstract] [Full Text] [Related]
55. Severe cerebellar swelling and thrombotic thrombocytopenic purpura associated with FK506. Tezcan H; Zimmer W; Fenstermaker R; Herzig GP; Schriber J Bone Marrow Transplant; 1998 Jan; 21(1):105-9. PubMed ID: 9486505 [TBL] [Abstract][Full Text] [Related]
56. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid. Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841 [TBL] [Abstract][Full Text] [Related]
57. Tacrolimus-induced thrombotic microangiopathy: natural history of a severe, acute vasculopathy. Carson JM; Newman ED; Farber JL; Filippone EJ Clin Nephrol; 2012 Jan; 77(1):79-84. PubMed ID: 22185974 [TBL] [Abstract][Full Text] [Related]
58. The ups and downs of sirolimus in kidney transplantation, and the importance of reporting negative findings. van Gelder T Neth J Med; 2007 Jan; 65(1):3-4. PubMed ID: 17293633 [No Abstract] [Full Text] [Related]
60. End of the line for sirolimus in liver transplant recipients with hepatitis C virus? De Simone P; Saliba F; Fischer L Liver Transpl; 2013 Feb; 19(2):236-7. PubMed ID: 23225519 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]